881 related articles for article (PubMed ID: 27273112)
1. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.
Zhou J; Ma X; Wang T; Zhai S
Osteoporos Int; 2016 Nov; 27(11):3289-3300. PubMed ID: 27273112
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Shi L; Min N; Wang F; Xue QY
Biomed Res Int; 2019; 2019():2594149. PubMed ID: 31828096
[TBL] [Abstract][Full Text] [Related]
3. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses.
Zhou J; Wang T; Zhao X; Miller DR; Zhai S
Rheumatol Ther; 2016 Jun; 3(1):117-128. PubMed ID: 27747517
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
7. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China).
Tan X; Wen F; Yang W; Xie JY; Ding LL; Mo YX
Menopause; 2019 Aug; 26(8):929-939. PubMed ID: 31021904
[TBL] [Abstract][Full Text] [Related]
9. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.
Iwamoto J; Sato Y; Takeda T; Matsumoto H
Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723
[TBL] [Abstract][Full Text] [Related]
11. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 Jun; 27(6):1989-98. PubMed ID: 26782683
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
14. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.
Freemantle N; Cooper C; Diez-Perez A; Gitlin M; Radcliffe H; Shepherd S; Roux C
Osteoporos Int; 2013 Jan; 24(1):209-17. PubMed ID: 22832638
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Nayak S; Greenspan SL
J Am Geriatr Soc; 2017 Mar; 65(3):490-495. PubMed ID: 28304090
[TBL] [Abstract][Full Text] [Related]
16. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Li P; Wu X; Li Y; Huang J
Clin Invest Med; 2022 Sep; 45(3):E14-22. PubMed ID: 36149052
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis.
Sanderson J; Martyn-St James M; Stevens J; Goka E; Wong R; Campbell F; Selby P; Gittoes N; Davis S
Bone; 2016 Aug; 89():52-58. PubMed ID: 27262775
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
